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AbstrAct
Introduction Based on epidemiological, immunological 
and pathology data, the idea that appendicitis is not 
necessarily a progressive disease is gaining ground. 
Two types are distinguished: simple and complicated 
appendicitis. Non-operative treatment (NOT) of children 
with simple appendicitis has been investigated in several 
small studies. So far, it is deemed safe. However, its 
effectiveness and effect on quality of life (QoL) have yet 
to be established in an adequately powered randomised 
trial. In this article, we provide the study protocol for 
the APAC (Antibiotics versus Primary Appendectomy in 
Children) trial.
Methods and analysis This multicentre, non-inferiority, 
randomised controlled trial randomises children aged 
7–17 years with imaging-confirmed simple appendicitis 
between appendectomy and NOT. Patients are recruited 
in 15 hospitals. The intended sample size, based on 
the primary outcome, rate of complications and a non-
inferiority margin of 5%, is 334 patients. NOT consists 
of intravenous antibiotics for 48–72 hours, daily blood 
tests and ultrasound follow-up. If the patient meets the 
predefined discharge criteria, antibiotic treatment is 
continued orally at home. Primary outcome is the rate 
of complications at 1-year follow-up. An independent 
adjudication committee will assess all complications 
and their relation to the allocated treatment. Secondary 
outcomes include, but are not limited to, delayed 
appendectomies, QoL, pain and (in)direct costs. The 
primary outcome will be analysed both according to the 
intention-to-treat principle and the per-protocol principle, 
and is presented with a one-sided 97.5% CI. We will 
use multiple logistic and linear regression for binary 
and continuous outcomes, respectively, to adjust for 
stratification factors.
Ethics and dissemination The protocol has been 
approved by the Medical Ethics Review Committee of the 
Academic Medical Center, Amsterdam. Data monitoring 
is performed by an independent institute and a Data 
Safety Monitoring Board has been assigned. Results will 
be presented in peer-reviewed academic journals and at 
(international) conferences.
trial registration number NCT02848820; NTR5977; 
Pre-results.
IntroductIon
Appendicitis is a common gastrointestinal 
disease with a lifetime incidence of 7%–9%.1 2 
Based on the assumption that urgent removal 
of the appendix is necessary to avoid progres-
sive inflammation with subsequent necrosis 
and perforation of the appendix, emergency 
appendectomy has been the standard of care 
since 1889. However, based on epidemio-
logical, immunological and pathology data, 
several experts have stated3–6 that appendi-
citis is not necessarily a progressive disease. 
Rather, they endorse the idea that two types of 
appendicitis exist: simple or uncomplicated 
appendicitis and complicated appendicitis. 
Over the years, there has been a shift towards 
non-operative treatment (NOT) strategies for 
diseases which were historically treated surgi-
cally, for instance, stomach ulcers and uncom-
plicated diverticulitis. More recently, NOT 
of acute uncomplicated appendicitis (AUA) 
has become the subject of investigation. This 
strategy consists of initial treatment with 
intravenous antibiotics and reserves appen-
dectomy for non-responders and those with 
recurrent appendicitis.
Several randomised controlled trials 
(RCT) looked at the NOT of AUA in the 
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Protocol
strengths and limitations of this study
 ► Meticulous selection of children with uncomplicated 
appendicitis using strict (evidence-based) criteria, 
including ultrasonography.
 ► Elaborate follow-up on patient, parent, hospital and 
economic levels.
 ► An independent adjudication committee assessing 
all complications and their relation to the allocated 
treatment.
 ► The non-inferiority design does not allow for a 
superiority comparison of the rate of complications.
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adult population. Results, however, vary. Most trials 
conclude that NOT is safe, but the reported reduc-
tion in complications varies from no significant differ-
ences7 8 to 86% reduction.9 Recurrent symptoms resulting 
in delayed appendectomy occur in roughly one in four 
patients.7 8 10 These numbers are interpreted in different 
ways, as illustrated by the conclusions of three recent 
systematic reviews, which range from indicating NOT as 
the preferred treatment10 to rejecting it as a routine treat-
ment due to insufficient knowledge about its impact on 
quality of life (QoL).8
Approximately one-third of all cases of appendicitis 
occur under the age of 20 years. Regarding the distribu-
tion of uncomplicated and complicated appendicitis in 
the paediatric population, the percentage of uncompli-
cated appendicitis is reported to range from 68% to 90% 
in children aged 5–18 years.2 11 The percentage of compli-
cated appendicitis increases with age,12 thus reducing 
the amount of patients suitable for initial NOT strategy. 
Potential benefits of initial NOT strategy might there-
fore be higher for the paediatric population than for the 
adult population. Data in the paediatric population on 
the outcome of NOT for uncomplicated appendicitis are 
scarce and consist mainly of uncontrolled studies with 
small patient numbers. Recently, a systematic review was 
published, including 10 studies (1 pilot RCT, 6 prospec-
tive cohorts and 3 retrospective cohorts) with a total of 
413 children treated with NOT.13 Overall complications 
where reported in five of the six comparative studies. One 
out of 175 (0.6%) patients in the NOT group suffered 
complications versus 9/239 (3.8%) patients in the 
primary appendectomy group. Follow-up ranged from 
8 weeks to 4 years, with 82% of the NOT patients not 
having undergone appendectomy at follow-up comple-
tion. Recurrent appendicitis occurred in 68/396 (17%) 
patients; this included 19 children who were treated with 
a second course of antibiotics.
The evidence regarding the outcome of NOT in the 
paediatric population is far from sufficient. As of today, 
apart from the trial described in this article, four large 
clinical studies (three RCTs14–16 and one prospective 
patient preference study17) are recruiting children for 
a comparison of primary appendectomy with NOT. In 
the APAC (Antibiotics versus Primary Appendectomy in 
Children) trial, we aim to evaluate the effectiveness of the 
initial NOT strategy (reserving appendectomy for those 
not responding or with recurrent disease) compared with 
immediate appendectomy in terms of complications, 
health-related QoL and costs in children aged 7–17 years 
with AUA.
MEthods And AnAlysIs
study design
The APAC trial is a multicentre, non-inferiority RCT. 
Blinding was not deemed feasible. The protocol was 
drafted in accordance with the SPIRIT (Standard 
Protocol Items: Recommendations for Interventional 
Trials) statements.18 This trial was registered at  Clinical-
Trials. gov (NCT02848820) and the Dutch Trial Registry 
(NTR5977) prior to the start of inclusion.
Patient selection
Eligible for inclusion are children 7–17 years old of both 
sexes, in whom an imaging-confirmed AUA is diagnosed 
in the emergency department of one of the participating 
hospitals.
Inclusion criteria
Definition of AUA is based on the following criteria:
 ► Clinical and biochemical criteria:
 – Localised tenderness in the right iliac fossa region
 – Normal/hyperactive bowel sounds
 – No guarding or palpable mass
 – Biochemical signs of infection
 – Elevated white blood cell count 
 – Elevated C-reactive protein (CRP)
 ► Ultrasound criteria to confirm the diagnosis of AUA:
 – A non-compressible, painful appendix with an 
outer diameter >6 mm
 – Secondary signs of inflammation, that is, infiltration 
of the surrounding fat
 – Hyperaemia within the appendiceal wall
In case the ultrasound is inconclusive, additional 
imaging (MRI or CAT scan) may be obtained.
Exclusion criteria
 ► Generalised peritonitis or sepsis (as defined by 
the international paediatric sepsis consensus 
conference19)
 ► Findings on imaging indicative of complex 
appendicitis:
 – Significant and/or unclear free fluid
 – Signs of perforation
 – Signs of intra-abdominal abscess or phlegmon
 ► Children with a suspicion of an appendiceal faecalith 
on imaging studies are excluded, because of its associ-
ation with a higher risk of NOT failure.20–23
 ► Ultrasound characteristics for an appendicolith are 
defined as an echogenic, well-defined focus within the 
appendix with posterior acoustic shadowing.
 ► Serious comorbidity such as cardiac or pulmonary 
disease with significant haemodynamic consequences, 
immunodeficiency, malignancy or sickle cell disease
 ► A history of non-operatively treated appendicitis
 ► Suspicion of an underlying malignancy or inflamma-
tory bowel disease
 ► Documented type 1 allergy to the antibiotics used
 ► A complex appendicitis risk score indicative of 
complex appendicitis
Complex appendicitis risk score
A paediatric scoring system is used24 predicting the risk of 
having complex appendicitis based on five preoperative 
variables: abdominal guarding, signs of complex appen-
dicitis on ultrasound, CRP level, temperature and days 
of abdominal pain. In an independent validation in a 
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box 1. Predefined discharge criteria. All criteria have to 
be met to allow patients to be discharged
Predefined discharge criteria (equal for both interventions):
1. Body temperature <38.0°C
2. NRS<4
3. Adequate oral intake
4. Able to mobilise
5. Consent of parents for discharge
Predefined discharge only for non-operative management:
6. Decreased leucocytosis
7. Decreased C-reactive protein
8. No signs of complex appendicitis on second ultrasound
Figure 1 Flow chart of non-operative management.   
CRP, C-reactive protein; WBC, white blood cell.
second paediatric cohort, a score below 4 had a negative 
predictive value of 98% (95% CI 88% to 100%). Children 
presenting with a score of 4 or higher will be excluded 
from this study because of the risk of having complicated 
appendicitis.
randomisation
After written informed consent from parents and child 
(assent from children under the age of 12), patients are 
randomised using the web-based randomisation program 
Castor Electronic Data Capture V.4.10,25 stratified by 
centre. A variable block algorithm is used to ensure 
concealment of allocation.
sample size calculation
A non-inferiority design is used based on the notion that 
NOT potentially has secondary advantages, for instance, 
cost reduction and less pain.26 We hypothesise that this 
might also be the case for QoL. It would thus be sufficient 
to demonstrate that the outcome in terms of complica-
tions is not worse in the NOT group compared with the 
immediate appendectomy group.
In our pilot study,27 we followed the children eligible 
for NOT who refused participation in that study and 
received immediate appendectomy instead of antibiotic 
treatment. The frequency of postoperative complications 
in this group at 1-year follow-up was approximately 10% 
(unpublished data), meaning that 90% was successfully 
treated without complications in the operative group. If 
the difference in complication rate between NOT and 
operative treatment is less than 5% in favour of appen-
dectomy, non-inferiority is assumed. We will not be testing 
for the superiority of NOT. Using a one-sided alpha of 
2.5% in accordance with the non-inferiority design, 150 
patients per group are needed to achieve 90% power for 
the exclusion of a difference in favour of the usual care 
group of more than 5%. Although in our pilot study27 
the dropout rate after 1 year was only 2%, we take into 
account a dropout rate of 10%. Therefore, the number of 
patients to be included is 334.
study setting and feasibility
Eligible patients are recruited in 15 hospitals across the 
Netherlands. This selection consists of both academic 
and large teaching hospitals. Inclusion started in January 
2017. Based on data supplied by the participating hospi-
tals, approximately 225 children per year will meet the 
inclusion criteria. In our pilot study, 57% of eligible 
patients participated. Taking these numbers into account, 
we expect to include 128 patients per year. We therefore 
expect to complete inclusion within 32 months. All of 
the clinical, biochemical and imaging assessments are 
part of the standard work-up for children suspected of 
having appendicitis in the Netherlands, as described in 
the Dutch national guideline.28
Interventions
Non-operative management
Antibiotic treatment consists of 48 hours of intra-
venous amoxicillin/clavulanic acid 25/2.5 mg/kg 
every 6 hours (maximum dose: 6000/600 mg/day) and 
gentamicin (7 mg/kg once daily). When the patient meets 
the predefined discharge criteria after 48 hours (box 1), 
he/she is discharged with oral antibiotics. If not, intra-
venous antibiotics are continued with a maximum total 
duration of 72 hours. Oral treatment consists of amoxi-
cillin/clavulanic acid 50/12.5 mg/kg in three daily doses 
(maximum dose: 1500/375 mg/day). Total duration of 
antibiotic treatment is 7 days.
To optimise early detection of NOT failure, white blood 
cell and CRP are measured every 24 hours during the 
time of administration of intravenous antibiotics. After 
48 hours, the abdominal ultrasound is repeated to check 
for signs of complicated appendicitis (figure 1).
A physician reassesses the patient twice daily. Vital 
parameters, including numeric rating scale (NRS) pain 
scores, are repeated every 6 hours. Intravenous fluid 
administration is protocolised and weight adjusted, with 
no oral intake during the first 12 hours. Pain medication 
is prescribed according to the national guideline.29
Predefined criteria are in place to define the indication 
for appendectomy (figure 1). In detail: a white blood cell 
count of more than 20×109/L, increasing white blood cell 
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count/CRP levels after 48 hours are criteria for clinical 
deterioration. An increasing pain level is defined as a 
higher NRS score than on admission despite of adequate 
pain medication according to protocol.
If the patient meets any of these criteria, the decision 
can be made to proceed with urgent appendectomy or 
to perform additional imaging studies. This decision is 
at the discretion of the surgeon in charge of the patient’s 
care and does not lie with study coordinators. However, 
it is common practice for the treating surgeon to consult 
with the study coordinators on the appropriate course of 
action.
Operative management
Intravenous fluids and pain medication are administered 
according to the same protocol as the NOT group. Anti-
biotic prophylaxis, operative approach and postoperative 
care are all according to local protocol. Postoperative 
antibiotics are only warranted in the event of an unex-
pected complex appendicitis. Discharge is allowed when 
the predefined discharge criteria have been met (box1).
outcoME And stAtIstIcAl AnAlysIs
Primary outcome
The primary outcome is defined as the complication rate at 
1-year follow-up. An independent adjudication committee 
will review all complications and adverse events to assess 
their relation to the allocated treatment. The adjudica-
tion committee will categorise all complications using the 
Clavien-Dindo system.30 The Clavien-Dindo system was 
developed for reporting surgical complications. However, 
we expect that all possible complications of NOT can 
also be categorised within the same system, making a 
comparison between the two groups more consistent. We 
will report both the overall complication rate as well as 
subgroups based on complication severity. Any form of 
delayed appendectomy is not considered a complication, 
as we consider appendectomy necessary in patients who 
do not respond to initial non-operative management. 
This includes early failure during initial admission and 
recurrent appendicitis after initial discharge. Complica-
tions as a result of a delayed appendectomy are included 
in the primary outcome.
Complications are defined as, but not limited to:
 ► Complications of antibiotic use: allergic reaction with 
the need for treatment, gastrointestinal symptoms 
with the need for treatment, secondary infections, 
and so on
 ► Need for surgical or radiological intervention other 
than appendectomy but related to appendicitis
 ► Readmission for an indication other than recurrent 
appendicitis but related to the allocated treatment
 ► Complications associated with appendectomy:
 – Surgical site infection: incisional and organ space 
as defined by the CDC (Centers for Disease Control 
and Prevention) criteria.31 We do not differentiate 
between superficial and deep-incisional infection
 – Stump leakage/stump appendicitis in need of 
antibiotic treatment or surgical/radiological 
intervention
 – Secondary bowel obstruction confirmed by imaging 
or per-operative diagnosis with the need for (non-
surgical) treatment. For instance, as a result of 
adhesions
 – Anaesthesia-related complications, such as 
pneumonia (in need of antibiotic treatment)
 – Incisional hernia. Defined as any abdominal 
wall gap with or without a bulge in the area of a 
postoperative scar perceptible or palpable by 
clinical examination or imaging
secondary outcomes
The rate of delayed appendectomy is reported as a 
secondary outcome. To evaluate the secondary endpoints, 
follow-up will take place at 7 days, 4 weeks, 6 months and 
1 year after randomisation. Other secondary outcomes 
are listed below:
 ► Appendectomy-related endpoints:
 – Percentage of patients not having to undergo 
appendectomy
 – Percentage of patients with a missed diagnosis of 
complex appendicitis
 – Percentage of patients having to undergo 
appendectomy during initial antibiotic course
 – Patients with recurrent appendicitis within 1 year 
(histopathologically confirmed)
 – Percentage of patients undergoing interval 
appendectomy (histopathologically no sign of 
recurrent appendicitis)
 ► Patient-related endpoints:
 – Level of pain: assessed by the NRS and total usage 
of pain medication on day 7
 – Health-related QoL: assessed with the Child Health 
Questionnaire-Child Form 87,32 the European 
Quality of Life-5 Dimensions-Youth questionnaire 
(child perspective) and the European Quality of 
Life-5 Dimensions-Proxy questionnaire (parent 
perspective)33
 – Patient satisfaction assessed with the Net Promoter 
Score and the validated Patient Satisfaction 
Questionnaire (PSQ-18)34
 – Number of days absent from school, social or sport 
events (patient level)
 – Number of days absent from work (parent level)
 – Total number of extra visits to the outpatient 
clinic, general practitioner’s office or emergency 
department for abdominal pain
 – Total length of hospital stay during the follow-up 
period, including admissions due to complications 
related to the allocated treatment. The length 
of initial hospital stay is included but will also be 
reported separately
 ► Cost-related endpoints:
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 – Non-medical and indirect costs at 1-year follow-up: 
using the Medical Consumption Questionnaire 
(iMCQ)35 and the Productivity Cost Questionnaire 
(iPCQ)36 adapted for use in children and parents
 – Actual healthcare costs: variables gathered are, 
but not limited to, number of follow-up outpatient 
clinic visits, number of general practitioner visits, 
number of emergency department visits and actual 
in-hospital generated costs
data analysis plan
The primary analysis will be done according to the 
intention-to-treat principle. A per-protocol analysis 
will be performed as well to prevent unjust rejection 
of the null hypothesis, which is a risk in non-inferi-
ority research.37 We only consider cases as a treatment 
arm crossover if the randomly assigned treatment is 
switched because of patient and/or parental prefer-
ence without their being medical grounds. Therefore, 
patients receiving an appendectomy because of clinical 
deterioration, abdominal complaints after discharge, or 
recurrent appendicitis will not be labelled as a cross-
over. We will use multiple logistic and linear regression 
analyses for binary and continuous outcomes, respec-
tively, to adjust for stratification factors. Differences in 
proportions, numbers needed to treat, and absolute 
and relative differences in continuous outcomes will be 
presented with the corresponding 95% CI, except for the 
percentage of patients with complications within 1 year 
(primary outcome), for which a one-sided 97.5% CI 
limit will be given in accordance with the non-inferi-
ority design. In a secondary analysis, the information 
recorded during the initial hospital stay will be analysed 
using multiple logistic regression analysis in order to 
identify potential predictive variables for NOT failure. 
Statistical analyses will be performed using IBM SPSS 
Statistics V.22.0 or higher (IBM, released 2013).
EthIcs And dIssEMInAtIon
data collection and confidentiality
All data are handled confidentially and access is strictly 
limited in accordance with the Dutch Personal Data 
Protection Act. All participants are assigned a unique 
study code, which is not based on the patient initials 
or birth date. The master sheet only contains the study 
code and patient identification information. Data are 
gathered through clinical observations, outpatient 
clinic visits, follow-up phone calls and online question-
naires. All data are collected via Castor Electronic Data 
Capture,25 a web-based electronic case record form, 
which is built, maintained and has an audit trail all 
according to Good Clinical Practice guidelines. All data 
will be stored for a period of at least 15 years.
Monitoring and safety
Reliable high-quality data are deemed of the upmost 
importance. The Clinical Research Bureau of the 
VU University Medical Centre will provide external moni-
toring, with monitoring visits of each participating centre 
at least once a year.
The accredited Medical Ethics Review Committee 
of the Academic Medical Center, Amsterdam (MERC 
AMC) will be informed annually. All (serious) adverse 
events, suspected unexpected serious adverse reac-
tions (SUSAR) and any other significant problems 
are reported to the MERC using an online submission 
system. To further assure the safety of participants, an 
independent Data Safety Monitoring Board (DSMB) is 
installed, consisting of a surgeon, a paediatrician and 
a statistician. They receive an overview of the primary 
outcome every 6 months, as well as serious adverse 
events, SUSARs and the number of patients having to 
undergo a delayed appendectomy. An interim analysis 
for efficacy will not be performed. If a serious concern 
arises for the safety of the patients in the trial, the DSMB 
can recommend early termination of the study. These 
agreements have been documented in a DSMB charter.
Ethics
The trial will be conducted in compliance with the 
current version of the Declaration of Helsinki, the 
ICH Good Clinical Practice guidelines E6(R1) and 
in accordance with the Dutch Medical Research 
Involving Human Subjects Act (WMO). 
Withdrawal
Subjects can withdraw from the study without expla-
nation at any time. They will be asked their reason for 
withdrawal, and they will be asked for permission to 
use their data. In case of withdrawal, the patient will 
be treated according to the national protocol, which 
would be an appendectomy. However, the surgeon 
in charge of care can decide otherwise in agreement 
with the patient and his or her family. Patients can 
also be withdrawn by the surgeon or the investigator 
for urgent medical reasons.
dissemination plan
Dispersion of the trial results will be accomplished by 
publication in an international peer-reviewed scien-
tific journal and by presentations at (international) 
conferences. When the results of the trial warrant 
changes in the standard treatment guidelines of 
simple appendicitis, we reckon that the widespread 
execution of the trial in centres throughout the 
Netherlands will aid in its implementation.
Implementation study
To ensure optimal implementation a problem anal-
ysis will be conducted parallel to this RCT, investi-
gating the promoting and obstructing determinants 
of implementation from patient, surgeon, organisa-
tional and social-political perspective. This qualitative 
study will include structured interviews with patients, 
parents, professionals and other stakeholders.
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dIscussIon
strengths and limitations of this study
This trial only includes patients with imaging-confirmed 
appendicitis, thus reducing the risk of including patients 
with other diagnoses, or those with a non-inflamed 
appendix. Since the implementation of a guideline in 
the Netherlands promoting preoperative imaging, the 
per-operative finding of non-inflamed appendices was 
reduced to 3.3%,38 which is low compared with, for example, 
the UK, where it is 20.6%.39 We postulate that our use 
of elaborate and, where possible, evidence-based patient 
selection methods enhances the chance of successful 
non-operative management. To warrant the safety of 
patients undergoing NOT, this protocol dictates system-
atic and frequent evaluation (by clinical assessment, 
laboratory tests and imaging studies). We expect this will 
identify patients not responding to the antibiotic treat-
ment at an early stage.
The non-inferiority design does not allow for a supe-
riority comparison for the rate of complications. The 
design choice was based on the argument that both treat-
ment strategies are 100% effective in treating appendi-
citis, because when antibiotic treatment is not successful 
and when recurrent appendicitis occurs, appendectomy is 
performed. We postulate that the non-operatively treated 
patients who do not require appendectomy will have a 
reduction in costs, better QoL and the avoidance of the 
complications associated with appendectomy. Essential 
for the possible acceptance of this new strategy is that it 
is not inferior when it comes to the risk of complications. 
To determine the severity of possible complications and 
their relation with the allocated treatment, we consider 
the support of an independent adjudication committee 
a great asset.
The inclusion and exclusion criteria of this trial 
are mostly based on data that allow for distinguishing 
complex from uncomplicated appendicitis. Criteria that 
predict the risk of NOT failure would be more adequate. 
However, more data and more experience are needed to 
be able to develop such criteria. Data from the APAC trial 
will also be used to analyse predictors of failure.
choice of primary outcome
Determining the appropriate primary outcome measure 
in studies comparing NOT with operative treatment 
remains challenging. In our opinion, both strategies 
will be effective in treating patients with appendicitis, 
and therefore effectiveness or failure is not an appro-
priate outcome measure. Therefore, we decided to use a 
composite outcome measure, that is, complications. Such 
outcome measures (morbidity and mortality) are neces-
sary in order to start the debate whether or not NOT 
strategy can be integrated in clinical practice.
Furthermore, our goal is to compare the initial NOT 
strategy (reserving an appendectomy for those not 
responding or with recurrent appendicitis) with direct 
operative treatment strategy. In this view, stating that 
delayed appendectomy for the indication of failed 
antibiotic treatment or recurrent appendicitis is a compli-
cation would not be appropriate as it is integrated in the 
treatment strategy. Postoperative complications after 
delayed appendectomy are however considered as compli-
cations of the initial NOT strategy. The amount of delayed 
appendectomies (for both non-responders and recurrent 
appendicitis) needs to be included in the debate whether 
or not initial NOT strategy can be implemented in daily 
practice. It is therefore reported as a secondary outcome.
complicated appendicitis
Reluctance of some surgeons towards NOT might be 
explained by the fear of missing complicated appendicitis 
and delaying appropriate treatment. In 4.5%–6.5% of 
the adult population treated with NOT who underwent 
delayed appendectomy, complicated appendicitis was 
found.7 10 The outcome in terms of postappendectomy 
complications after delayed appendectomy (6.9%) is 
comparable to that for primary appendectomy (8.8%).8
Exclusion of patients with appendiceal faecalith
We excluded patients with a suspicion of an appendiceal 
faecalith on preoperative imaging studies because it is 
associated with a higher failure rate of NOT. In the adult 
population, a NOT failure rate of 50% after 1 month was 
reported in the group with a faecalith versus 14% in the 
group without a faecalith.20 One study only including chil-
dren with appendicitis and a faecalith on imaging had to 
terminate inclusions early because of a NOT failure rate 
of 60% at a median of 4.7 months’ follow-up.23 Faecaliths 
are also associated with a higher long-term recurrence 
risk in children, with recurrences of 47.4% vs 23.7%.21
Follow-up/long-term effects
Information regarding long-term results of NOT in 
simple appendicitis is limited and it is scarce in chil-
dren. One study in children with an average follow-up of 
4.3 years reported that 22 of 78 (29%) children treated 
with NOT experienced recurrent appendicitis,21 with a 
median time to recurrence of 6 months. Eight per cent 
of all non-operatively treated children experienced 
recurrence after more than 1 year. The APAC trial has a 
follow-up of 1 year. However, all participants who have not 
been operated at the end of the study will be asked to 
participate in long-term follow-up. The long-term effects 
in children of losing the function of the appendix have 
also not yet been cleared up. The appendix might play a 
role in immunity and there is evidence that it is involved 
in preserving a healthy gut microbiome.40
choice of antibiotic regime
Most of the data on antibiotic susceptibility in appendi-
citis is derived from studies in adults, patients with compli-
cated appendicitis and mixed patient groups. There is 
some evidence available concerning children. A study 
analysing cultures from children in Ireland with compli-
cated appendicitis revealed that the combination therapy 
of amoxicillin-clavulanic acid and aminoglycosides 
would be appropriate in 99% of children with bacterial 
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appendicitis-related peritonitis.41 Since antibiotic resis-
tance rates are greatly dependent on geography, we can 
expect comparable or even better results in the Nether-
lands, considering it has the lowest rates of antibiotic use 
in Europe.42 Combined with a low rate of complications 
and extensive experience with amoxicillin-clavulanic acid 
and gentamicin, we consider it the most sensible regime. 
Further research is carried out by our research group 
analysing the microbiome in simple and complicated 
appendicitis. Hopefully, this will contribute in deter-
mining the best antibiotic regime. If NOT of appendicitis 
is shown to be non-inferior in this trial, further research 
should determine the most sensible regime and treat-
ment duration. The first pilot RCT evaluating outpatient 
conservative management in a mixed group (children 
and adults) has already been published.43
Antibiotic resistance
A possible downside of NOT as opposed to surgery could 
be increased antibiotic resistance.44 Interestingly, a study 
evaluating bacterial resistance in complicated appendi-
citis in children showed no significant increase in resis-
tance rates over the past 20 years.45 How this translates to 
bacterial resistance when simple appendicitis is treated 
with antibiotics is unclear. The use of multidrug treat-
ment regimens has been pointed out as one of the possi-
bilities to reduce the development of resistant bacteria.46 
Our choice for amoxicillin-clavulanic acid and genta-
micin prevents us from having to use so-called reserve 
antibiotics, unlike most of the other known studies in 
children, in which for instance piperacillin-tazobactam 
is the drug of choice. Also when the symptoms do not 
resolve under the chosen antibiotic regimen, appendec-
tomy is performed; we do not switch to other antibiotics.
Value of histological evaluation
An occasionally mentioned argument8 against NOT of 
appendicitis is the risk of missing other underlying causes 
of appendicitis, such as a carcinoid. One study repeated 
the abdominal ultrasound in children 1–3 months after 
NOT to ensure the diameter of the appendix returned 
to normal.21 The value of this strategy is unknown. In an 
analysis of 241 histopathological appendectomy samples 
in children with simple appendicitis, 4 (1.6%) showed 
unexpected findings.47 Three parasitic infections and 
one Walthard cell rest were found; none of the find-
ings required further treatment or investigation. The 
frequency of appendiceal carcinoid tumours in children 
undergoing appendectomy was 0.2%,48 and in less than 
20% of these cases lymphovascular or mesenteric involve-
ment was present. This seems a negligible risk and it is yet 
unclear if patients who are excluded or unresponsive to 
NOT are also the patients with the highest risk of having 
a malignancy as underlying cause.
Unique for the APAC trial is its primary outcome 
measure; total number of complications after 1 year. 
Delayed appendectomy or recurrence is not reported 
as the primary endpoint or as a complication. Because 
in our opinion there is a place for the appendectomy 
in non-operative management as a step-up approach 
for children unresponsive to antibiotic treatment. As a 
result, 8 or 9 out of every 10 children with uncomplicated 
appendicitis would no longer have to undergo an appen-
dectomy. Furthermore, if we are able to identify specific 
predictive preoperative variables, we might identify a 
group of patients with even better (long-term) outcomes. 
Finally, this trial should answer the question whether the 
advantages of NOT are also reflected in the reported QoL 
and diminished costs.
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